Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (471-480 of 869) with videos related to

Pageof 87
Sort By:
Blood|April 9, 2005
A clinically relevant SCID-hu in vivo model of human multiple myelomaPierfrancesco Tassone, Paola Neri, Daniel R Carrasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2017
Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateCharles A Schiffer, Kari Bohlke, Meghan Delaney, et al.
Blood Cancer Journal|March 28, 2019
Deciphering the chronology of copy number alterations in Multiple MyelomaAnil Aktas Samur, Stephane Minvielle, Masood Shammas, et al.
Clinical and Experimental Medicine|July 8, 2023
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugsXili Liu, Maria Moscvin, Seungeun Oh, et al.
Blood|July 12, 2003
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistanceDharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Blood Advances|September 8, 2020
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical modelsShih-Feng Cho, Liang Lin, Lijie Xing, et al.
Cancer Research|July 5, 2006
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironmentYu-Tzu Tai, Xian-Feng Li, Iris Breitkreutz, et al.
Blood Cancer Journal|December 19, 2022
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factorsAnil Aktas Samur, Mariateresa Fulciniti, Herve Avet-Loiseau, et al.
Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.
Blood|December 8, 2009
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcomeJames J Driscoll, Dheeraj Pelluru, Konstantinos Lefkimmiatis, et al.
Pageof 87

Showing results (471-480 of 869) with videos related to

Sort By:
Pageof 87
Blood|April 9, 2005
A clinically relevant SCID-hu in vivo model of human multiple myelomaPierfrancesco Tassone, Paola Neri, Daniel R Carrasco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2017
Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateCharles A Schiffer, Kari Bohlke, Meghan Delaney, et al.
Blood Cancer Journal|March 28, 2019
Deciphering the chronology of copy number alterations in Multiple MyelomaAnil Aktas Samur, Stephane Minvielle, Masood Shammas, et al.
Clinical and Experimental Medicine|July 8, 2023
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugsXili Liu, Maria Moscvin, Seungeun Oh, et al.
Blood|July 12, 2003
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistanceDharminder Chauhan, Guilan Li, Teru Hideshima, et al.
Blood Advances|September 8, 2020
The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical modelsShih-Feng Cho, Liang Lin, Lijie Xing, et al.
Cancer Research|July 5, 2006
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironmentYu-Tzu Tai, Xian-Feng Li, Iris Breitkreutz, et al.
Blood Cancer Journal|December 19, 2022
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factorsAnil Aktas Samur, Mariateresa Fulciniti, Herve Avet-Loiseau, et al.
Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.
Blood|December 8, 2009
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcomeJames J Driscoll, Dheeraj Pelluru, Konstantinos Lefkimmiatis, et al.
Pageof 87